Ab therapy of AML: Native anti-CD33 Ab and drug conjugates

Cytotherapy

Volumn 10, Issue 1, 2008, Pages 7-12

  Jurcic, J G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; Gemtuzumab ozogamicin; HuM195; Lintuzumab; Monoclonal antibodies

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; INTERLEUKIN 2; LINTUZUMAB; MITOXANTRONE; MONOCLONAL ANTIBODY M 195; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; SGN 33; TOPOTECAN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT RESPIRATORY DISTRESS SYNDROME; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG BINDING; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOCYTOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; LOW DRUG DOSE; LUNG EDEMA; MAXIMUM TOLERATED DOSE; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PLASMA HALF LIFE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE;

EID: 38349127317     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240701519012     Document Type: Review

References (44)

1. Cassileth, PA, Harrington, DP and Appelbaum, FR (1998) Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med, 339, pp. 1649-1656.
2. Stockerl-Goldstein, KE and Blume, KG. (1999) Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia. Hematopoietic Cell Transplantation, pp. 823-834. Blackwell Science, Oxford
3. Sabbath, KD, Ball, ED and Larcom, P. (1985) Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J Clin Invest, 75, pp. 746-756.
4. Andrews, RG, Takahashi, M. and Segal, GM (1986) The L4F3 antigen is expressed by unipotent colony-forming cells but not by their precursors. Blood, 68, pp. 1030-1035.
5. Omary, MB, Trowbridge, IS and Battifora, HA. (1980) Human homologue of murine T-200 glycoprotein. J Exp Med, 152, pp. 842-852.
6. Wahren, B., Gadler, F. and Gahrton, G. (1983) NCA: A differentiation antigen of myelopoietic cells in human and hominoid monkeys. Ann NY Acad Sci, 417, pp. 344-358.
7. McLaughlin, P., Grillo-Lopez, AJ and Link, BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol, 16, pp. 2825-2833.
8. Keating, MJ, Flinn, I. and Jain, V. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 99, pp. 3554-3561.
9. Weisburg, J., Roepe, PD, Dzekunov, S. and Scheinberg, DA. (1999) Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells. J Biol Chem, 274, pp. 10877-10888.
10. Scheinberg, DA, Lovett, D. and Divgi, CR (1991) A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol, 9, pp. 478-490.
11. Caron, PC, Co, MS and Bull, MK (1992) Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res, 52, pp. 6761-6767.
12. Caron, PC, Jurcic, JG and Scott, AM (1994) A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity. Blood, 83, pp. 1760-1768.
13. Xu, Y. and Scheinberg, DA. (1995) Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model. Clin Cancer Res, 1, pp. 1179-1187.
14. Caron, PC, Dumont, L. and Scheinberg, DA. (1998) Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res, 4, pp. 1421-1428.
15. Feldman, E., Kalaycio, M. and Weiner, G. (2003) Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia, 17, pp. 314-318.
16. Vitale, C., Romagnani, C. and Puccetti, A. (2001) Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: Engagement of CD33 induces apoptosis of leukemic cells. Proc Natl Acad Science USA, 98, pp. 5764-5769.
17. Balaian, L., Zhong, RK and Ball, ED. (2003) The inhibitory effect of anti-CD33 monoclonal antibodies of AML cell growth correlates with Syk and/or ZAP-70 expression. Exp Hematol, 5, pp. 363-371.
18. Raza, A., Jurcic, JG and Roboz, G. (2006) Increased dose intensity of SGN-33, a humanized monoclonal antibody targeting CD33, is active and well-tolerated in patients with acute myeloid leukemia and myelodysplastic syndrome. Blood, 108, pp. 221b-222b.
19. Jurcic, JG, Nimer, SD and Scheinberg, DA (2001) Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood, 98, pp. 2651-2656.
20. Jurcic, JG, DeBlasio, T. and Dumont, L. (2000) Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res, 6, pp. 372-380.
21. Jurcic, JG. (2001) Antibody therapy for residual disease in acute myelogenous leukemia. Crit Rev Oncol, 38, pp. 37-45.
22. Mulford, DA, Maslak, PG and Weiss, MA (2003) Reducing standard postremission chemotherapy in acute promyelocytic leukemia with risk-adapted therapy. Blood, 102, pp. 619a-20a.
23. Balaian, L. and Ball, ED. (2005) Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways. Exp Hematol, 33, pp. 199-211.
24. Feldman, EJ, Brandwein, J. and Stone, R. (2005) Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol, 23, pp. 4110-4116.
25. Caron, PC, Lai, L. and Scheinberg, DA. (1995) Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (HuM195) (anti-CD33) in myelogenous leukemia. Clin Cancer Res, 1, pp. 63-70.
26. Calligiuri, MA, Murray, C. and Soiffer, RJ (1991) Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol, 9, pp. 2110-2119.
27. Kossman, SE, Scheinberg, DA and Jurcic, JG (1999) A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia. Clin Cancer Res, 5, pp. 2748-2755.
28. Zein, N., Sinha, AM, McGahren, WJ and Ellestad, GA. (1988) Calicheamicin gamma 1I: An antitumor antibiotic that cleaves double-stranded DNA site specifically. Science, 240, pp. 1198-1201.
29. Sievers, EL, Appelbaum, FR and Spielberger, RT (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 93, pp. 3678-3684.
30. Larson, RA, Siievers, EL and Stadtmauer, EA (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer, 104, pp. 1442-1452.
31. Bross, PF, Beitz, J. and Chen, G. (2001) Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res, 7, pp. 1490-1496.
32. Wadleigh, M., Richardson, PG and Zahrieh, D. (2003) Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 102, pp. 1578-1582.
33. Rajvanshi, P., Schulman, H. and Sievers, E. (2002) Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood, 99, pp. 10-14.
34. Amadori, S., Suciu, S. and Stasi, R. (2005) Gemtuzumab ozogamicin as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: Final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia groups. Leukemia, 19, pp. 1768-1773.
35. Estey, EH, Thall, PF and Giles, FJ (2002) Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood, 99, pp. 4343-4349.
36. Kell, WJ, Burnett, AK and Chopra, R. (2003) A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood, 102, pp. 4277-4283.
37. DeAngelo, DJ, Schiffer, C. and Stone, R. (2002) Interim analysis of a phase II study of the safety and efficacy of gemtuzumab ozogamicin ('Mylotarg') given in combination with cytarabine and daunorubicin in patients <60 years old with untreated acute myeloid leukemia. Blood, 100, p. 198a.
38. Burnett, AK, Kell, WJ and Goldstone, AH (2006) The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial. Blood, 108, p. 8a.
39. Tsimberidou, A., Cortes, J. and Thomas, D. (2003) Gemtuzumab ozogamicin, fludarabine, cytarabine, and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res, 27, pp. 893-897.
40. Apostolidou, E., Cortes, J. and Tsimberidou, A. (2003) Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res, 27, pp. 887-891.
41. Cortes, J., Tsimberidou, AM and Alvarez, R. (2002) Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol, 50, pp. 497-500.
42. Estey, E., Giles, FJ and Beran, M. (2002) Experience with gemtuzumab ozogamicin ('Mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood, 99, pp. 4222-4224.
43. LoCoco, F., Cimino, G. and Breccia, M. (2004) Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood, pp. 1995-1999.
44. Aribi, A., Kantarjian, HM and Estey, EH (2007) Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer, 109, pp. 1355-1359.